Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2025)

Vivos Therapeutics has reported EBITDA Margin over the past 6 years, most recently at 172.12% for Q4 2025.

  • Quarterly EBITDA Margin fell 9895.0% to 172.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 110.07% through Dec 2025, down 3840.0% year-over-year, with the annual reading at 110.04% for FY2025, 3905.0% down from the prior year.
  • EBITDA Margin was 172.12% for Q4 2025 at Vivos Therapeutics, down from 63.9% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 200.5% in Q4 2021 and troughed at 176.7% in Q1 2022.
  • The 5-year median for EBITDA Margin is 119.18% (2021), against an average of 98.18%.
  • Year-over-year, EBITDA Margin surged 38987bps in 2021 and then plummeted -34640bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 200.5% in 2021, then tumbled by -173bps to 145.9% in 2022, then rose by 17bps to 121.09% in 2023, then surged by 40bps to 73.17% in 2024, then plummeted by -135bps to 172.12% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBITDA Margin are 172.12% (Q4 2025), 63.9% (Q3 2025), and 119.5% (Q2 2025).